A retrospective study of paclitaxel combining nedaplatin chemotherapy for esophageal cancer

Anti-Cancer Drugs

Volumn 26, Issue 1, 2015, Pages 101-105

  Du, Jianping ^a   Hu, Changlu ^c   Zhang, Yuliu ^b   Hu, Bing ^a   Wang, Fen ^a   Zhang, Yumei ^c  

^a ANHUI PROVINCIAL HOSPITAL   (China)

^b Thoracic Surgery Department Dingyuan People's Hospital   (China)

^c ANHUI PROVINCIAL CANCER HOSPITAL   (China)

Author keywords

esophageal cancer; nedaplatin; paclitaxel

Indexed keywords

CREATININE; NEDAPLATIN; PACLITAXEL; ANTINEOPLASTIC AGENT; PLATINUM COMPLEX;

ADULT; AGED; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CREATININE BLOOD LEVEL; DIARRHEA; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FATIGUE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; PAIN; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SENSORY NEUROPATHY; SIDE EFFECT; STOMATITIS; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT RESPONSE; CARCINOMA, SQUAMOUS CELL; CHEMICALLY INDUCED; ESOPHAGEAL NEOPLASMS; METASTASIS; MIDDLE AGED; PATHOLOGY;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; DISEASE-FREE SURVIVAL; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEUTROPENIA; ORGANOPLATINUM COMPOUNDS; PACLITAXEL; RETROSPECTIVE STUDIES;

EID: 84925510601     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0000000000000170     Document Type: Article

References (21)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61:69-90.
2. Mauer AM, Weichselbaum RR. Multimodality therapy for carcinoma of the esophagus. In: Posner MC, Vokes EE, Weichselbaum RR, editors. American cancer society atlas. Hamilton, ON: BC Dekker; 2002. pp. 157-184.
3. Kelsen DP, Ginsberg R, Pajak TF, Sheahan DG, Gunderson L, Mortimer J, et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med 1998; 339:1979-1984.
4. Herskovic A, Martz K, al-Sarraf M, Leichman L, Brindle J, Vaitkevicius V, et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 1992;326:1593-1598.
5. Koshiyama M, Kinezaki M, Uchida T, Sumitomo M. Chemosensitivity testing of a novel platinum analog, nedaplatin (254-S), in human gynecological carcinomas: a comparison with cisplatin. Anticancer Res 2005;25:4499-4502.
6. Hasegawa Y, Takanashi S, Okudera K, Aoki M, Basaki K, Kondo H, et al. Weekly paclitaxel and nedaplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer: a phase I/II study. Jpn J Clin Oncol 2004; 34:647-653.
7. Ohashi T, Ohnishi M, Tanahashi S, Murai M. Efficacy and toxicity of concurrent chemoradiotherapy with nedaplatin and S-1 for head and neck cancer. Jpn J Clin Oncol 2011; 41:348-352.
8. Satoh T, Tsushima K, Saitoh S, Hizawa Y, Tamura Y, Fukuda S, et al. A case of advanced esophageal cancer showing a long-term complete response with chemotherapy with nedaplatin alone. Jpn J Clin Oncol 1999;29:106-108.
9. Matsumoto H, Hirabayashi Y, Kubota H, Murakami H, Higashida M, Haruma K, et al. A combined therapy with docetaxel and nedaplatin for relapsed and metastatic esophageal carcinoma. Anticancer Res 2012;32:1827-1831.
10. Kikuchi J, Yamazaki K, Kinoshita I, Asahina H, Imura M, Kikuchi E, et al. Phase I trial of carboplatin and weekly paclitaxel in patients with advanced non-small-cell lung cancer. Jpn J Clin Oncol 2004; 34:505-509.
11. Park YH, Ryoo BY, Choi SJ, Yang SH, Kim HT. A phase II study of paclitaxel plus cisplatin chemotherapy in an unfavourable group of patients with cancer of unknown primary site. Jpn J Clin Oncol 2004; 34:681-685.
12. Yamamoto N, Tsurutani J, Yoshimura N, Asai G, Moriyama A, Nakagawa K, et al. Phase II study of weekly paclitaxel for relapsed and refractory small cell lung cancer. Anticancer Res 2006; 26:777-781.
13. Viens P, Petit T, Yovine A, Bougnoux P, Deplanque G, Cottu PH, et al. A phase II study of a paclitaxel and oxaliplatin combination in platinum-sensitive recurrent advanced ovarian cancer patients. Ann Oncol 2006; 17:429-436.
14. Yamaguchi K, Nakagawa S, Yabusaki H, Nashimoto A. Combination chemotherapy with 5-fluorouracil, cisplatin and paclitaxel for pretreated patients with advanced gastric cancer. Anticancer Res 2007;27:3535-3539.
15. Ilson DH, Wadleigh RG, Leichman LP, Kelsen DP. Paclitaxel given by a weekly 1-h infusion in advanced esophageal cancer. Ann Oncol 2007;18:898-902.
16. Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. New York: John Wiley and Sons; 1980. pp. 14-15.
17. Brookmeyer R, Crowley J. A confidence interval for the median survival time. Biometrics 1982; 38:29-41.
18. Bleiberg H, Conroy T, Paillot B, Lacave AJ, Blijham G, Jacob JH, et al. Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer. Eur J Cancer 1997; 33:1216-1220.
19. Shimada M, Itamochi H, Kigawa J. Nedaplatin: a cisplatin derivative in cancer chemotherapy. Cancer Manag Res 2013; 5:67-76.
20. Cao W, Xu C, Lou G, Jiang J, Zhao S, Geng M, et al. A phase II study of paclitaxel and nedaplatin as first-line chemotherapy in patients with advanced esophageal cancer. Jpn J Clin Oncol 2009; 39:582-587.
21. Bouché O, Ychou M, Burtin P, Bedenne L, Ducreux M, Lebreton G, et al. Fédération Francophone de Cancérologie Digestive Group. Adjuvant chemotherapy with 5-fluorouracil and cisplatin compared with surgery alone for gastric cancer: 7-year results of the FFCD randomized phase III trial (8801). Ann Oncol 2005; 16:1488-1497.